Success Story: Advancing Drug Discovery for Precision Medicine: NIW Approval Secured for a Molecular Biology Expert from China
Client’s Testimonial:
“Very prompt and thorough answers to my questions all the time.”
On September 1st, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Senior Director in the field of Molecular Biology (Approval Notice).
General Field: Molecular Biology
Position at the Time of Case Filing: Senior Director
Country of Origin: China
State of Residence at the Time of Filing: Massachusetts
Approval Notice Date: September 1st, 2026
Processing Time: 2 months, 2 days (Premium Processing Requested)
Case Summary:
We are pleased to share the NIW approval of a molecular biology expert whose work advances the discovery of targeted therapeutic approaches for complex diseases. The client’s proposed endeavor focuses on developing drug candidates for disease-related targets with elevated expression to support new therapies for cancer, rare genetic diseases, and metabolic diseases.
At the time of filing, the client was working as a Senior Director while continuing research in molecular biology, protein engineering, and therapeutic discovery approaches for precision medicine applications.
Research with National Importance
The client’s research addresses critical healthcare challenges by developing more selective therapeutic strategies for diseases with significant unmet medical needs. By advancing drug candidates that can target biologically important molecules with high specificity, her work supports the development of improved therapies and aligns with U.S. priorities in biotechnology, health innovation, and precision medicine.
Academic Contributions and Recognition
At the time of filing, the client had authored 16 peer-reviewed journal articles (3 first-authored and 1 co-first-authored), 3 abstracts, and 4 patent applications. Her published work received 658 citations, demonstrating recognition from researchers studying molecular biology, plant biology, and related biomedical fields.
Her publications have appeared in highly regarded journals spanning molecular biology, biotechnology, and related biological sciences, including The Plant Cell, Critical Reviews in Biotechnology, European Journal of Cancer, The Plant Journal, and Frontiers in Plant Science. These publications demonstrate her broad expertise in molecular mechanisms, protein interactions, and biological systems relevant to therapeutic discovery.
Recognition from Experts
Experts highlighted the client’s extensive expertise in molecular biology and her ability to apply advanced biological approaches toward impactful scientific and therapeutic discoveries.
One expert noted:
“Her extraordinary expertise and major accomplishments undeniably mark her as one of the best-suited researchers capable of making advancements in plant production and durability.”
This endorsement reinforces the client’s longstanding expertise in molecular mechanisms, genetic analysis, and biological systems. Combined with her publication record, citation impact, patent contributions, and research experience, the expert recognition further demonstrates her ability to advance innovative molecular biology research and therapeutic discovery.
NIW Approval and Outlook
The I-140 NIW petition was filed on June 30th, 2026, with Direct Premium Processing, and approved on September 1st, 2026. The approval recognized the national importance of the client’s work in molecular biology, particularly her efforts to advance drug candidates for disease-related targets and support the development of more precise therapeutic strategies.
This outcome supports the client’s continued efforts to advance biotechnology, precision medicine, and innovative therapeutic discovery in the United States. We congratulate her on this approval and wish her continued success in advancing biomedical research.